Neuroinflammation and autoimmune mechanisms have been recognized to have a key part in the pathogenesis of Parkinson’s disease (PD). Therefore, we evaluated the role of Toll-like receptors (TLRs) as a link between inflammation and autoimmunity in PD. We performed an in vivo model of PD, by 1-metil 4-fenil 1,2,3,6-tetraidro-piridina (MPTP) administration for 7 days, in single KO mice for TLR7, TLR 8 and TLR9; and in double KO mice for TLR 7/8-/-. All animals were compared with WT animals used as a control group. The result obtained demonstrated that the genetic absence of TLR 7 and 8 modified PD pathway increasing the immunoreactivity for TH and DAT compared to PD groups and decreasing microglia and astrocytes activation. Moreover, the deletion of TLR7 and TLR8 significantly reduced T-cell production in the substantia nigra and lymph nodes, suggesting a reduction of T cell activation. Therefore, our result highlights a possibility that an immunotherapy approach by using a dual antagonist of TLR 7 and 8, could be considered as a possible target to develop new therapies for Parkinson diseases.
Michela Campolo, Irene Paterniti, Alessia Filippone, Carmelo Biondo, Giuseppe Mancuso, Salvatore Cuzzocrea and Emanuela Esposito
Journal of Translational Neurosciences received 46 citations as per google scholar report